Empliciti ratings & reviews

Elotuzumab (Murine)
Company: BMS
Brand: Empliciti
Drug class: Antineoplastic and Immunomodulating Agents
+4 more
Antineoplastic and Immunomodulating Agents, Antineoplastics, Antineoplastic Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Antineoplastic Monoclonal Antibodies Targeting Signaling Lymphocytic Activation Moleculr Family 7 (SLAMF7)
Overall rating
3.5
full star full star full star half star empty star
Ranked #12
Physician ratings
  • Efficacy: effective for its intended use
  • Safety: safe to use in humans
  • Tolerability: low drug side effects
  • Accessibility: insurance/payer coverage, cost, affordability,formulary coverage, availability in your hospital or practice setting
  • Adherence: patient compliance with treatment
Efficacy
3.6/5
Safety
3.6/5
Tolerability
3.6/5
Accessibility
3.2/5
Adherence
3.6/5

Sermo AI Overview

  • Empliciti's efficacy in treating multiple myeloma is viewed variably by healthcare professionals, with some noting better results when combined with therapies like Revlimid. However, there are also concerns regarding its safety and manageability in certain cases.
  • Patients generally find Empliciti accessible and manageable, contributing to good adherence scores. This suggests that despite some concerns about efficacy and safety, many patients can sustain their treatment effectively.
  • Was this summary helpful?
Based on insights from Sermo’s triple verified physicians

Description

Empliciti is a brand name for the drug elotuzumab, which is a humanized monoclonal antibody directed to SLAMF7. It is formulated as a sterile lyophilized powder for injection, available in 300 mg and 400 mg single-dose vials, and is administered intravenously after reconstitution and dilution. Key inactive ingredients include citric acid monohydrate, polysorbate 80, sodium citrate, and sucrose. Empliciti is designed to be used as part of cancer treatment regimens due to its mechanism involving SLAMF7, a protein relevant in the treatment of conditions like multiple myeloma.

Source: This information is sourced from FDA and powered by AI

Dosage & Administration

How should I use this medication?

This medication is injected into a vein. It is given by your care team in a hospital or clinic setting.

Talk to your care team about the use of this medication in children. Special care may be needed.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.

NOTE: This medicine is only for you. Do not share this medicine with others.

What if I miss a dose?

Keep appointments for follow-up doses. It is important not to miss your dose. Call your care team if you are unable to keep an appointment.

Where should I keep my medication?

This medication is given in a hospital or clinic. It will not be stored at home.

NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.

Side Effects

What side effects may I notice from receiving this medication?

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • Infection—fever, chills, cough, sore throat, wounds that don't heal, pain or trouble when passing urine, general feeling of discomfort or being unwell
  • Infusion reactions—chest pain, shortness of breath or trouble breathing, feeling faint or lightheaded
  • Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue

Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):

  • Constipation
  • Diarrhea
  • Fatigue
  • Headache
  • Loss of appetite
  • Pain, tingling, or numbness in the hands or feet

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings & Precautions

What should I tell my care team before I take this medication?

They need to know if you have any of these conditions:

  • Hepatic disease
  • Infection
  • An unusual or allergic reaction to elotuzumab, other medications, foods, dyes, or preservatives
  • Pregnant or trying to get pregnant
  • Breast-feeding

What may interact with this medication?

Interactions have not been studied.

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medication?

You condition will be monitored carefully while you are receiving this medication.

This medication may make you feel generally unwell. This is not uncommon as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your care team tells you to stop.

This medication can cause serious allergic reactions. To reduce the risk, your care team may give you other medications to take before receiving this one. Be sure to follow the directions from your care team.

You may need blood work while taking this medication.

This medication can affect the results of some tests used to determine treatment response; extra tests may be needed to evaluate response.

Talk to your care team about your risk of cancer. You may be more at risk for certain types of cancer if you take this medication.

Talk to your care team if you wish to become pregnant or think you might be pregnant. This medication can cause serious birth defects if taken during pregnancy. A reliable form of contraception is recommended while taking this medication. Talk to your care team about effective forms of contraception.

Do not breast-feed while taking this medication.

Source: This information is sourced from Elsevier Inc.

Disclaimer

The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.

Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.

Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.

Terms of use

  1. Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool). 

  2. Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc.  Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”).  Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.

  3. Authorized User acknowledges and agrees that the Elsevier Products are designed for and are intended to be used by those residing in the United States, and that the information contained in the Elsevier Products does not comply with any laws or practices outside of the United States. You assume all responsibilities, duties, and obligations for any treatment, decision, or advice made or given to third parties as a result of the use or application of the Elsevier Products outside of the United States, and Sermo, Elsevier and its affiliates, subsidiaries, agents and suppliers will incur no liability for any use or application of the Products by Authorized Users outside of the United States.

Welcome to Sermo's Drug Ratings

Previously only for members, Sermo Drug Ratings are now openly available to all healthcare providers, patients, and industry professionals to support better healthcare decisions.

Clinical expertise
Insights based on real prescribing experience from triple-verified practicing physicians only
Detailed insights
Ratings on key attributes including efficacy, safety, tolerability, accessibility, and adherence
Unbiased reviews
Independent, physician-only reviews, free from pharmaceutical industry influence